Browse the corpus

REFERENCES Anderson JE, Appelbaum FR, Schoch G, et al, “Allogeneic Marrow Transplantation for Myelodysplastic Syndrome With Advanced Disease Morphology: A Phase II Study of Busulfan, Cyclophosphamide, and Total Body-Irradiation and Analysis of Prognostic Factors,” J Clin Oncol , 1996, 14(1):220-6. [PubMed 8558201 ] Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 169. Booth BP, Rahman A, Dagher R, et al, “Population Pharmacokinetic-Based Dosing of Intravenous Busulfan in Pediatric Patients,” J Clin Pharmacol , 2007, 47(1):101-11. [PubMed 17192508 ] Cassileth PA, Andersen J, Lazarus HM, et al, “Autologous Bone Marrow Transplant in Acute Myeloid Leukemia in First Remission,” J Clin Oncol , 1993, 11(2):314-9. [PubMed 8426209 ] Cassileth PA, Harrington DP, Appelbaum FR, et al, “Chemotherapy Compared With Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission,” N Engl J Med , 1998, 339(23):1649-56. [PubMed 9834301 ] Fabris F and Randi ML, “Essential Thrombocythemia: Past and Present,” Intern Emerg Med , 2009, 4(5):381-8. [PubMed 19636672 ] Fermand JP, Katsahian S, Divine M, et al, “High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe,” J Clin Oncol , 2005, 23(36):9227-33. [PubMed 16275936 ] Ho VT, Aldridge J, Kim HT, et al, Comparison of Tacrolimus and Sirolimus (Tac/Sir) Versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-Versus-Host Disease Prophylaxis After Reduced-Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation,” Biol Blood Marrow Transplant , 2009, 15(7):844-50. [PubMed 19539216 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013.

Ho VT, Aldridge J, Kim HT, et al, Comparison of Tacrolimus and Sirolimus (Tac/Sir) Versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-Versus-Host Disease Prophylaxis After Reduced-Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation,” Biol Blood Marrow Transplant , 2009, 15(7):844-50. [PubMed 19539216 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Pulsipher MA, Boucher KM, Wall D, et al, “Reduced-Intensity Allogeneic Transplantation in Pediatric Patients Ineligible for Myeloablative Therapy: Results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313,” Blood , 2009, 114(7):1429-36. [PubMed 19528536 ] Radich JP, Gooley T, Bensinger W, et al, “HLA-Matched Related Hematopoietic Cell Transplantation for Chronic-Phase CML Using a Targeted Busulfan and Cyclophosphamide Preparative Regimen,” Blood , 2003, 102(1):31-5. [PubMed 12595317 ] Regazzi MB, Locatelli F, Buggia I, et al, “Disposition of High-Dose Busulfan in Pediatric Patients Undergoing Bone Marrow Transplantation,” Clin Pharmacol Ther , 1993, 54(1):45-52. [PubMed 8330465 ] Seddon BM, Cassoni AM, Galloway MJ, et al, “Fatal Radiation Myelopathy After High-Dose Busulfan and Melphalan Chemotherapy and Radiotherapy for Ewing’s Sarcoma: A Review of the Literature and Implications for Practice,” Clin Oncol (R Coll Radiol) , 2005, 17(5):385-90. Shaw PJ, Nath C, Berry A, et al, “Busulphan Given as Four Single Daily Doses of 150 mg/m 2 Is Safe and Effective in Children of All Ages,” Bone Marrow Transplant , 2004, 34(3):197-205. [PubMed 15195074 ] Socié G, Clift RA, Blaise D, et al, “Busulfan Plus Cyclophosphamide Compared With Total-Body Irradiation Plus Cyclophosphamide Before Marrow Transplantation for Myeloid Leukemia: Long-Term Follow-Up of 4 Randomized Studies,” Blood , 2001, 98(13):3569-74. [PubMed 11739158 ] Tefferi A, “Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series: Polycythemia Vera and Essential Thrombocythemia: 2011 Update on Diagnosis, Risk-Stratification, and Management,” Am J Hematol , 2011, 86(3):292-301. [PubMed 21351120 ]

Socié G, Clift RA, Blaise D, et al, “Busulfan Plus Cyclophosphamide Compared With Total-Body Irradiation Plus Cyclophosphamide Before Marrow Transplantation for Myeloid Leukemia: Long-Term Follow-Up of 4 Randomized Studies,” Blood , 2001, 98(13):3569-74. [PubMed 11739158 ] Tefferi A, “Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series: Polycythemia Vera and Essential Thrombocythemia: 2011 Update on Diagnosis, Risk-Stratification, and Management,” Am J Hematol , 2011, 86(3):292-301. [PubMed 21351120 ] Tosti A, Piraccini BM, Vincenzi C, et al, “Permanent Alopecia After Busulfan Chemotherapy,” Br J Dermatol , 2005, 152(5):1056-8. [PubMed 15888171 ] Vassal G, Gouyette A, Hartmann O, et al, “Pharmacokinetics of High-Dose Busulfan in Children,” Cancer Chemother Pharmacol , 1989, 24(6):386-90. [PubMed 2791192 ] Topic 9173 Version 42.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]